In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI

Affiliations

¹ Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
² Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
³ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
⁴ Laboratory for Dermatohistology and Oral Pathology, Munich, Germany.
⁵ Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Comment

Konstantina Delli et al. Ann Rheum Dis. 2016 Jun.

. 2016 Jun;75(6):e34.

doi: 10.1136/annrheumdis-2016-209317. Epub 2016 Mar 9.

¹ Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
² Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
³ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
⁴ Laboratory for Dermatohistology and Oral Pathology, Munich, Germany.
⁵ Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

No abstract available

Keywords: B cells; Sjøgren's Syndrome; Treatment.

Comment on

Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK. Delli K, et al. Ann Rheum Dis. 2016 Nov;75(11):1933-1938. doi: 10.1136/annrheumdis-2015-208304. Epub 2016 Jan 12. Ann Rheum Dis. 2016. PMID: 26757748 Clinical Trial.
Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
Cornec D, Costa S, Devauchelle-Pensec V, Chiche L, Saraux A, Pers JO. Cornec D, et al. Ann Rheum Dis. 2016 Jun;75(6):e33. doi: 10.1136/annrheumdis-2016-209300. Epub 2016 Feb 19. Ann Rheum Dis. 2016. PMID: 26895746 No abstract available.